Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer drug more effective in women than men
Updated results of a phase II study of Xyotax in combination with carboplatin among 35 women and 39 men with advanced non-small cell lung cancer (NSCLC) confirmed the
Updated results of a phase II study of Xyotax in combination with carboplatin among 35 women and 39 men with advanced non-small cell lung cancer (NSCLC) confirmed the
The phase I/II clinical trial is designed to evaluate the IV formulation’s safety, tolerability, pharmacokinetics and preliminary efficacy in 60 patients, pre-screened for response to oral zileuton, whose
Genentech has requested a priority review designation from the FDA, which if granted, requires the FDA to take action on the application within six months. The sBLA submission
Having beaten off competition from Ranbaxy Laboratories, its Indian rival, Dr Reddy’s will acquire Betapharm from British private equity group 3i. Dr Reddy’s said that the acquisition would
Keryx in-licensed the rights to Zerenex from Panion & BF Biotech, a drug development company based in Taiwan. In accordance with the terms of the agreement, Keryx will
Merck expects FDA action on the NDA by mid-October, and is moving forward as planned with filings in countries outside the US. Januvia is an investigational once-daily medicine
Under the new agreement, researchers from both companies will evaluate the full range of immunity elicited by virus-like particle (VLP) influenza vaccines developed at Novavax. In addition, scientists
The data were presented by Dr Jef Jones from the MD Anderson Cancer, at the tenth annual international congress on hematologic malignancies in Whistler, British Columbia. In this
Abbott now has a total of six targets under investigation from the strategic collaboration established between Celera Genomics and Abbott to discover, develop and commercialize therapies for the
Overall, patients who received tetrabenazin, which is currently being reviewed by the FDA, were six times as likely to be considered by their doctors to have improved considerably,